Health AI Central
Share:
Peer-Reviewed Publication
Sci Rep2023;13(1):13121.August 12, 2023Journal Article

Using AI and Gd-EOB-DTPA-enhanced MR imaging to assess liver function, comparing the MELIF score with the ALBI score.

Carolina Río Bártulos1, Karin Senk2, Ragnar Bade3, Mona Schumacher3, Nico Kaiser3, Jan Plath3, Mathis Planert4, Christian Stroszczynski2, Jan Woetzel3, Philipp Wiggermann4
1Institut Für Röntgendiagnostik Und Nuklearmedizin, Städtisches Klinikum Braunschweig gGmbH, 38126, Braunschweig, Germany. c.rio@skbs.de.
2Institut Für Röntgendiagnostik, Universitätsklinikum Regensburg, 93053, Regensburg, Germany.
3MeVis Medical Solutions AG, 28359, Bremen, Germany.
4Institut Für Röntgendiagnostik Und Nuklearmedizin, Städtisches Klinikum Braunschweig gGmbH, 38126, Braunschweig, Germany.
PubMed PMC DOI PDF

Abstract

Monitoring disease progression is particularly important for determining the optimal treatment strategy in patients with liver disease. Especially for patients with diseases that have a reversible course, there is a lack of suitable tools for monitoring liver function. The development and establishment of such tools is very important, especially in view of the expected increase in such diseases in…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.